ArticlebioRxiv : the preprint server for biology2025
Not all alloantibodies are created equal: IgG glycosylation and severity of antibody-mediated rejection in kidney transplantation.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Antibody-mediated rejection (AMR) is a leading cause of kidney transplant (KT) failure, driven by donor-specific anti-HLA antibodies (DSA). However, not all patients with DSA experience accelerated graft loss, suggesting that factors beyond antibody presence influence AMR severity. Post-translational modifications, particularly glycosylation of Immunoglobulin-G (IgG), play a critical role in modulating antibody function. This study investigates the association between IgG glycosylation profiles and the risk and severity of AMR in KT recipients. Methods: We prospectively analyzed 65 KT patients, including 26 with acute AMR (aAMR), 27 with chronic-active AMR (caAMR), and 12 controls without rejection. IgG glycosylation was quantified using lectin-based ELISA, focusing on mannose, fucose, sialic acid, and bisecting N-acetylglucosamine (GlcNAc) levels. Results: Results showed that bisecting GlcNAc levels of total IgG were significantly higher in caAMR patients than controls (p=0.019) and aAMR patients (p=0.045). Multivariable analysis revealed that higher bisecting GlcNAc levels of IgG were independently associated with glomerulitis [g-score, OR: 2.7 (95%CI: 1.2-6.7), p=0.019] and chronic glomerulopathy [cg-score, OR: 2.8 (95%CI: 1.3-7.5), p=0.021], independent of DSA presence. Conclusions: These findings indicate an association between IgG glycosylation, particularly bisecting GlcNAc, and AMR severity. IgG glycosylation profiles could serve as biomarkers for AMR risk and severity, offering new insights into the mechanisms of AMR and potential therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.